227 related articles for article (PubMed ID: 8595501)
1. AIDS pathogenesis: from models to viral dynamics in patients.
Nowak MA
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S1-5. PubMed ID: 8595501
[TBL] [Abstract][Full Text] [Related]
2. Molecular biological assessment methods and understanding the course of the HIV infection.
Katzenstein TL
APMIS Suppl; 2003; (114):1-37. PubMed ID: 14626050
[TBL] [Abstract][Full Text] [Related]
3. HIV pathogenesis and treatment strategies.
Vella S
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S20-3. PubMed ID: 8595503
[TBL] [Abstract][Full Text] [Related]
4. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
5. Replication of a pre-existing resistant HIV-1 subpopulation in vivo after introduction of a strong selective drug pressure.
de Jong MD; Schuurman R; Lange JM; Boucher CA
Antivir Ther; 1996 Jan; 1(1):33-41. PubMed ID: 11322257
[TBL] [Abstract][Full Text] [Related]
6. Anti-viral drug treatment: dynamics of resistance in free virus and infected cell populations.
Nowak MA; Bonhoeffer S; Shaw GM; May RM
J Theor Biol; 1997 Jan; 184(2):203-17. PubMed ID: 9059598
[TBL] [Abstract][Full Text] [Related]
7. Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals.
Cohen OJ; Pantaleo G; Schwartzentruber DJ; Graziosi C; Vaccarezza M; Fauci AS
J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 1():S6-14. PubMed ID: 8595512
[TBL] [Abstract][Full Text] [Related]
8. Determinants of the natural history of human immunodeficiency virus type 1 infection.
Phair JP
J Infect Dis; 1999 Mar; 179 Suppl 2():S384-6. PubMed ID: 10081512
[TBL] [Abstract][Full Text] [Related]
9. New information on HIV rapid turnover--what does it mean?
James JS
AIDS Treat News; 1995 Jan; (No 215):1-4. PubMed ID: 11362214
[TBL] [Abstract][Full Text] [Related]
10. [Brief analytical review of additional possible mechanisms in the pathogenesis of AIDS].
Legitimo A; Baldini M; Consolini R; Biver P; Crimaldi G; Macchia P
Pathologica; 1994 Apr; 86(2):119-27. PubMed ID: 7936754
[TBL] [Abstract][Full Text] [Related]
11. Decrease of replicative capacity of HIV isolates after genotypic guided change of therapy.
Sarmati L; Nicastri E; Montano M; Dori L; Buonomini AR; d'Ettorre G; Gatti F; Parisi SG; Vullo V; Andreoni M
J Med Virol; 2004 Apr; 72(4):511-6. PubMed ID: 14981751
[TBL] [Abstract][Full Text] [Related]
12. Advances in HIV/AIDS therapy.
Johnson SC; Gerber JG
Adv Intern Med; 2000; 45():1-40. PubMed ID: 10635044
[TBL] [Abstract][Full Text] [Related]
13. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
Martinez-Picado J; Martínez MA
Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
[TBL] [Abstract][Full Text] [Related]
14. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and natural history of HIV infection.
Sleasman JW; Goodenow MM
J Fla Med Assoc; 1991 Oct; 78(10):678-81. PubMed ID: 1753233
[TBL] [Abstract][Full Text] [Related]
16. Higher CD4+ T cell counts associated with low viral pol replication capacity among treatment-naive adults in early HIV-1 infection.
Barbour JD; Hecht FM; Wrin T; Segal MR; Ramstead CA; Liegler TJ; Busch MP; Petropoulos CJ; Hellmann NS; Kahn JO; Grant RM
J Infect Dis; 2004 Jul; 190(2):251-6. PubMed ID: 15216458
[TBL] [Abstract][Full Text] [Related]
17. Roaches of inner space.
Gilden D
GMHC Treat Issues; 1995 Oct; 9(10):1, 14-6. PubMed ID: 11362912
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
19. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
20. Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068.
Jacobson JM; Pat Bucy R; Spritzler J; Saag MS; Eron JJ; Coombs RW; Wang R; Fox L; Johnson VA; Cu-Uvin S; Cohn SE; Mildvan D; O'Neill D; Janik J; Purdue L; O'Connor DK; Vita CD; Frank I;
J Infect Dis; 2006 Sep; 194(5):623-32. PubMed ID: 16897661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
